Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016206039> ?p ?o ?g. }
- W2016206039 endingPage "594" @default.
- W2016206039 startingPage "585" @default.
- W2016206039 abstract "Combretastatin A-4 (CA-4) is a naturally occurring microtubular-destabilising agent that possesses potent anti-tumour and anti-vascular properties both in vitro and in vivo. Clinical trials to date indicate that its water-soluble prodrug, combretastatin A-4 phosphate (CA-4P), is well tolerated at therapeutically useful doses. However, the stilbenoid structure of CA-4, consisting of two phenyl rings linked by an ethylene bridge, renders the compound readily susceptible to isomerisation from its biologically active cis-conformation to its more thermodynamically stable but inactive trans-isomer. To circumvent this problem, we synthesised a series of cis-restricted CA-4 analogues. Replacement of the ethylene bridge with a 1,4-diaryl-2-azetidinone (β-lactam) ring provided a rigid scaffold thus preventing cis-trans isomerisation. We previously documented that these tubulin-depolymerising β-lactam compounds potently induced cell cycle arrest and apoptosis in a variety of cancerous cell lines (including those displaying multidrug resistance) and ex vivo patient samples, whilst exerting only minimal toxicity to normal cells. The purpose of this study was to elucidate the effect of the β-lactam compounds on both tumour vascularisation and tumour cell migration, two critical elements that occur during the growth and metastatic progression of tumours. We established that two representative β-lactam compounds, CA-104 and CA-432, exerted both anti-endothelial effects [G2/M arrest and apoptosis of primary human umbilical vein endothelial cells (HUVECs)] and anti-angiogenic effects [inhibition of HUVEC migration and differentiation and reduced vascular endothelial growth factor (VEGF) release from MDA-MB-231 breast adenocarcinoma cells]. In addition, we established that lead analogue, CA-432, abrogated the migration of MDA-MB-231 cells indicating an anti-metastatic function for these compounds. In summary, our results to date collectively indicate that these cis-restricted β-lactam CA-4 analogues may prove to be useful alternatives to CA-4 in the treatment of cancer but with the added advantage of improved stability of the cis-isomer." @default.
- W2016206039 created "2016-06-24" @default.
- W2016206039 creator A5008119223 @default.
- W2016206039 creator A5011539571 @default.
- W2016206039 creator A5029287111 @default.
- W2016206039 creator A5039437331 @default.
- W2016206039 creator A5072733929 @default.
- W2016206039 creator A5073924686 @default.
- W2016206039 creator A5074800205 @default.
- W2016206039 creator A5078313965 @default.
- W2016206039 date "2012-12-10" @default.
- W2016206039 modified "2023-10-14" @default.
- W2016206039 title "Novel cis-restricted β-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro" @default.
- W2016206039 cites W103592546 @default.
- W2016206039 cites W1520425169 @default.
- W2016206039 cites W1591187753 @default.
- W2016206039 cites W1662899239 @default.
- W2016206039 cites W1725865716 @default.
- W2016206039 cites W1966726954 @default.
- W2016206039 cites W1970199745 @default.
- W2016206039 cites W1987361445 @default.
- W2016206039 cites W1994297035 @default.
- W2016206039 cites W1996910230 @default.
- W2016206039 cites W1998593069 @default.
- W2016206039 cites W2006273356 @default.
- W2016206039 cites W2010293565 @default.
- W2016206039 cites W2015102053 @default.
- W2016206039 cites W2017627019 @default.
- W2016206039 cites W2022682037 @default.
- W2016206039 cites W2024304301 @default.
- W2016206039 cites W2030488247 @default.
- W2016206039 cites W2033103610 @default.
- W2016206039 cites W2037060916 @default.
- W2016206039 cites W2040044819 @default.
- W2016206039 cites W2040197644 @default.
- W2016206039 cites W2042148981 @default.
- W2016206039 cites W2044503668 @default.
- W2016206039 cites W2056944384 @default.
- W2016206039 cites W2074738520 @default.
- W2016206039 cites W2087073539 @default.
- W2016206039 cites W2093199254 @default.
- W2016206039 cites W2098228945 @default.
- W2016206039 cites W2112911107 @default.
- W2016206039 cites W2116251667 @default.
- W2016206039 cites W2118887889 @default.
- W2016206039 cites W2120895512 @default.
- W2016206039 cites W2128773741 @default.
- W2016206039 cites W2130349349 @default.
- W2016206039 cites W2134425816 @default.
- W2016206039 cites W2148990197 @default.
- W2016206039 cites W2149213586 @default.
- W2016206039 cites W2151195433 @default.
- W2016206039 cites W2153804947 @default.
- W2016206039 cites W2155056678 @default.
- W2016206039 cites W2160912185 @default.
- W2016206039 cites W2163453798 @default.
- W2016206039 cites W2171765375 @default.
- W2016206039 cites W2333842658 @default.
- W2016206039 cites W4250428608 @default.
- W2016206039 doi "https://doi.org/10.3892/or.2012.2181" @default.
- W2016206039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23232969" @default.
- W2016206039 hasPublicationYear "2012" @default.
- W2016206039 type Work @default.
- W2016206039 sameAs 2016206039 @default.
- W2016206039 citedByCount "19" @default.
- W2016206039 countsByYear W20162060392014 @default.
- W2016206039 countsByYear W20162060392015 @default.
- W2016206039 countsByYear W20162060392016 @default.
- W2016206039 countsByYear W20162060392018 @default.
- W2016206039 countsByYear W20162060392019 @default.
- W2016206039 countsByYear W20162060392020 @default.
- W2016206039 countsByYear W20162060392021 @default.
- W2016206039 countsByYear W20162060392023 @default.
- W2016206039 crossrefType "journal-article" @default.
- W2016206039 hasAuthorship W2016206039A5008119223 @default.
- W2016206039 hasAuthorship W2016206039A5011539571 @default.
- W2016206039 hasAuthorship W2016206039A5029287111 @default.
- W2016206039 hasAuthorship W2016206039A5039437331 @default.
- W2016206039 hasAuthorship W2016206039A5072733929 @default.
- W2016206039 hasAuthorship W2016206039A5073924686 @default.
- W2016206039 hasAuthorship W2016206039A5074800205 @default.
- W2016206039 hasAuthorship W2016206039A5078313965 @default.
- W2016206039 hasBestOaLocation W20162060391 @default.
- W2016206039 hasConcept C105696609 @default.
- W2016206039 hasConcept C108215921 @default.
- W2016206039 hasConcept C123012128 @default.
- W2016206039 hasConcept C150903083 @default.
- W2016206039 hasConcept C185592680 @default.
- W2016206039 hasConcept C190283241 @default.
- W2016206039 hasConcept C202751555 @default.
- W2016206039 hasConcept C20418707 @default.
- W2016206039 hasConcept C207001950 @default.
- W2016206039 hasConcept C2776131168 @default.
- W2016206039 hasConcept C2777411675 @default.
- W2016206039 hasConcept C2778275628 @default.
- W2016206039 hasConcept C2780394083 @default.
- W2016206039 hasConcept C29537977 @default.
- W2016206039 hasConcept C502942594 @default.